DR. LIJI JOMON PARASSERIL

Dr. MOHAN RAJAN, Dr.Supriya Dabir

Abstract

DME is the most common cause of vision loss in patients with diabetic retinopathy. In our study we assessed functional and morphological changes like BCVA, central macular thickness(CMT), superficial capillary density(SCP) and FAZ area in patients with DME before and after 3 monthly intravitreal anti-VEGF(Ranibizumab) injection using OCT angiography. We quantified the parameters like vessel density, perfusion density and FAZ area in the SCP of patients with DME. We found that there is significant improvement in visual acuity and decrease in CMT following administration of ranibizumab injection for 3 consecutive months. There was a decrease in the vessel density, perfusion density and FAZ area after 3 monthly injections. It was also found that there was no significant relation between BCVA and the 3 parameters, namely, vessel density, perfusion density and FAZ area and hence these parameters cannot be used to predict visual improvement in eyes with DME after ranibizumab treatment.